K. Sandy Pang

Transport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2.

Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption.

Retention of transporter activities in cryopreserved, isolated rat hepatocytes.

Moment analysis of metabolic heterogeneity: conjugation of benzoate with glycine in rat liver studied by multiple indicator dilution technique.

Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.

Influence of P-glycoprotein, transfer clearances, and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis.

Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series).

The roles of transporters and enzymes in hepatic drug processing.

Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1.

Binding of acellular, native and cross-linked human hemoglobins to haptoglobin: enhanced distribution and clearance in the rat.

Vascular binding, blood flow, transporter, and enzyme interactions on the processing of digoxin in rat liver.

Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused rat liver preparation.

Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor.

Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.

P-glycoprotein and an unstirred water layer barring digoxin absorption in the vascularly perfused rat small intestine preparation: induction studies with pregnenolone-16alpha-carbonitrile.

An integrated approach to model hepatic drug clearance.

Increased estrogen sulfation of estradiol 17beta-D-glucuronide in metastatic tumor rat livers.

Transporters, enzymes, and enalapril removal in a rat (CC531-induced) liver metastatic model.

Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.

Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study.

Role of haptoglobin on the uptake of native and beta-chain [trimesoyl-(Lys82)beta-(Lys82)beta] cross-linked human hemoglobins in isolated perfused rat livers.

A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibition.

The Caco-2 cell monolayer: usefulness and limitations.

Formed and preformed metabolites: facts and comparisons.

Safety testing of metabolites: Expectations and outcomes.

Disparity in intestine disposition between formed and preformed metabolites and implications: a theoretical study.

Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer.

Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver.

Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver.

1alpha,25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo.

Interplay of transporters and enzymes in drug and metabolite processing.

Effects of 1alpha,25-dihydroxyvitamin D3 on transporters and enzymes of the rat intestine and kidney in vivo.

Interplay of phase II enzymes and transporters in futile cycling: influence of multidrug resistance-associated protein 2-mediated excretion of estradiol 17beta-D-glucuronide and its 3-sulfate metabolite on net sulfation in perfused TR(-) and Wistar rat liver preparations.

Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates.

Interplay of transporters and enzymes in the Caco-2 cell monolayer: I. effect of altered apical secretion.

The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices.

Comparative effects of doxercalciferol (1α-hydroxyvitamin D₂) versus calcitriol (1α,25-dihydroxyvitamin D₃) on the expression of transporters and enzymes in the rat in vivo.

Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism.

1α,25-dihydroxyvitamin D3 on intestinal transporter function: studies with the rat everted intestinal sac.

1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo.

Fraction absorbed (Fabs ): different connotations and confusion for the literature?

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay!

Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells.

Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model.

Why we need proper PBPK models to examine intestine and liver oral drug absorption.

1α,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells.

Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.

Comparative effects of 1α-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on transporters and enzymes in fxr(+/+) and fxr(-/-) mice.

Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol.

1α,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer's disease.

Effects of 1α,25-dihydroxyvitamin D3 , the natural vitamin D receptor ligand, on the pharmacokinetics of cefdinir and cefadroxil, organic anion transporter substrates, in rat.

Vitamin D receptor activation induces P-glycoprotein and increases brain efflux of quinidine: an intracerebral microdialysis study in conscious rats.

Dealing with the complex drug-drug interactions: towards mechanistic models.

PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation.

Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment.

PKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.

Response to letter to the editor on "fractional clearance for verapamil N-demethylation in the isolated rat liver preparation".

Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1α,25-Dihydroxyvitamin D3 in Mice.

Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.

Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo.

Functional Integrity of the Chimeric (Humanized) Mouse Liver: Enzyme Zonation, Physiologic Spaces, and Hepatic Enzymes and Transporters.

Disrupted Murine Gut-to-Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models.

Physiologically based pharmacokinetic modeling revealed minimal codeine intestinal metabolism in first-pass removal in rats.

Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.

Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury.

Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?

Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist.